Anti-fibrotic Drugs for Crohn's Disease: Ready for Prime Time?

被引：5

作者：

Argollo, Marjorie ^{[1
]}

Gilardi, Daniela ^{[1
]}

Roda, Giulia ^{[1
]}

Fiorino, Gionata ^{[1
,2
]}

Peyrin-Biroulet, Laurent ^{[3
,4
]}

Danese, Silvio ^{[1
,2
]}

机构：

[1] Humanitas Clin & Res Ctr, IBD Ctr, Milan, Italy

[2] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[3] Lorraine Univ, Nancy Univ Hosp, Dept Gastroenterol, Vandoeuvre Les Nancy, France

[4] Lorraine Univ, Nancy Univ Hosp, INSERM U954, Vandoeuvre Les Nancy, France

来源：

CURRENT PHARMACEUTICAL DESIGN | 2019年 / 25卷 / 01期

关键词：

Anti-fibrotic drugs; Crohn's disease; intestinal fibrosis; treatment; stenotic lesions; chronic inflammation; FIBROBLAST ACTIVATION PROTEIN; WEIGHTED MAGNETIC-RESONANCE; INFLAMMATORY-BOWEL-DISEASE; HEPATIC STELLATE CELLS; GROWTH-FACTOR-BETA; INTESTINAL FIBROSIS; MATRIX METALLOPROTEINASES; POSTOPERATIVE RECURRENCE; MOLECULAR-MECHANISMS; SYSTEMIC-SCLEROSIS;

D O I：

10.2174/1381612825666190308100844

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Intestinal fibrosis, driven by chronic inflammation in Crohn's disease, can be defined as an excessive accumulation of extracellular matrix in the affected gut segment ultimately leading to an impaired wound healing and cumulative tissue damage, possibly resulting in organ dysfunction, formation of stenotic lesions and necessity of surgical intervention. Despite continuous advances in developing novel treatment modalities targeting different pathways to control chronic gut inflammation in CD, no effective anti-fibrotic agents have been released, to date. Thus, a better understanding of the molecular and cellular mechanisms underlying intestinal fibrosis is key to move this area of investigation forward.

引用

页码：47 / 56

页数：10

共 147 条

[1] Fibroblast activation protein:: a serine protease expressed at the remodeling interface in idiopathic pulmonary flbrosis [J].